Literature DB >> 1697125

Cross-reactive protection against influenza A virus infections by an NS1-specific CTL clone.

K Kuwano1, M Tamura, F A Ennis.   

Abstract

An influenza A subtype cross-reactive CTL clone (A-11) was established following stimulation of A/PR/8 virus-immune spleen cells of Balb/C (H-2d) mice. This T cell clone lysed target cells infected with influenza viruses of the H1, H2, or H3 subtypes, and recognizes a conserved epitope on the NS1 protein. The clone is restricted by the H-2Ld allele. Adoptive transfer of A-11 significantly reduced virus titers in the lungs of mice infected with influenza A viruses of the H1, H2, or H3 subtypes. These results suggest that the conserved epitope on NS1 which is recognized by A-11 may be a useful component to consider for inclusion in experimental cross-reactive influenza vaccines.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1697125     DOI： 10.1016/0042-6822(90)90391-4

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  10 in total

1.  Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Alan L Rothman; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-02-26       Impact factor: 3.641

2.  Definition of amino acid residues on the epitope responsible for recognition by influenza A virus H1-specific, H2-specific, and H1- and H2-cross-reactive murine cytotoxic T-lymphocyte clones.

Authors:  M Tamura; K Kuwano; I Kurane; F A Ennis
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

3.  The reovirus nonstructural protein sigma1NS is recognized by murine cytotoxic T lymphocytes.

Authors:  L M Hoffman; K T Hogan; L W Cashdollar
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets.

Authors:  S H Seo; R G Webster
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Authors:  Behazine Combadière; Annika Vogt; Brice Mahé; Dominique Costagliola; Sabrina Hadam; Olivia Bonduelle; Wolfram Sterry; Shlomo Staszewski; Hans Schaefer; Sylvie van der Werf; Christine Katlama; Brigitte Autran; Ulrike Blume-Peytavi
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

6.  Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans.

Authors:  W E Demkowicz; F A Ennis
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients.

Authors:  Masanori Terajima; John Cruz; Anita M Leporati; Laura Orphin; Jenny Aurielle B Babon; Mary Dawn T Co; Pamela Pazoles; Julie Jameson; Francis A Ennis
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

8.  Human cytotoxic T-lymphocyte repertoire to influenza A viruses.

Authors:  J Jameson; J Cruz; F A Ennis
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Karin M Green; James Potts; Anita M Leporati; Jenny Aurielle B Babon; James E Evans; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

10.  Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.

Authors:  C M Lawson; J R Bennink; N P Restifo; J W Yewdell; B R Murphy
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.